HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study

SIMPLE SUMMARY: Breast cancers (BCs) with a HER2 immunohistochemical score of 1+ or 2+ with negative in situ hybridization are referred as HER2-low BCs. The knowledge about the biological and clinical characteristics of HER2-low BCs is still limited and controversial. Despite that new anti-HER2 anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlino, Francesca, Diana, Anna, Ventriglia, Anna, Piccolo, Antonio, Mocerino, Carmela, Riccardi, Ferdinando, Bilancia, Domenico, Giotta, Francesco, Antoniol, Giulio, Famiglietti, Vincenzo, Feliciano, Salvatore, Cangiano, Rodolfo, Lobianco, Lorenzo, Pellegrino, Benedetta, De Vita, Ferdinando, Ciardiello, Fortunato, Orditura, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599946/
https://www.ncbi.nlm.nih.gov/pubmed/36291765
http://dx.doi.org/10.3390/cancers14204981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599946/
https://www.ncbi.nlm.nih.gov/pubmed/36291765
http://dx.doi.org/10.3390/cancers14204981

Ejemplares similares